Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer

D. Katsaros, W. Cho, R. Singal, S. Fracchioli, I. A. Rigault De La Longrais, R. Arisio, M. Massobrio, M. Smith, Wenxin - Zheng, J. Glass, H. Yu

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Objective. Methylation of p16 promoter was evaluated in ovarian cancer to determine the role of p16 methylation in ovarian cancer prognosis. Methods. Two hundred and forty-nine patients with primary epithelial ovarian cancer were selected for the study; these patients were followed for a median of 31 months. Genomic DNA extracted from fresh frozen tumor tissues were treated with sodium bisulfite and were analyzed for p16 methylation using methylation-specific PCR (MSP). Cox regression survival analysis was performed to examine the associations of p16 methylation with progression-free and overall survivals. Results. Of the 249 patients, 100 (40%) were tested positive for p16 promoter methylation. The status of p16 methylation did not change significantly with patient age, disease stage, histological grade, residual tumor size, and debulking results, although p16 methylation seemed to occur more often in patients with advanced diseases or aggressive tumors. Compared to those without p16 methylation, patients with p16 methylation had significantly higher risk for disease progression (P = 0.01). The relative risk for progression was 1.69 (95% CI: 1.12-2.54), and the association remained statistically significant (RR = 1.54, 95% CI: 1.01-2.34) after adjusting for clinical and pathological variables. The risk for death was also higher in methylation positive patients than in methylation negative patients (RR = 1.33, 95% CI: 0.88-2.00), but the difference was not statistically significant. Conclusion. The study suggests that promoter methylation in the p16 gene is associated with ovarian cancer progression, and evaluation of p16 methylation may have values in predicting ovarian cancer prognosis.

Original languageEnglish (US)
Pages (from-to)685-692
Number of pages8
JournalGynecologic Oncology
Volume94
Issue number3
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Tumor Suppressor Genes
Methylation
Ovarian Neoplasms
Ovarian epithelial cancer
p16 Genes
Residual Neoplasm
Survival Analysis
Disease-Free Survival
Disease Progression
Neoplasms
Regression Analysis

Keywords

  • Epithelial ovarian cancer
  • Methylation
  • p16

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Katsaros, D., Cho, W., Singal, R., Fracchioli, S., Rigault De La Longrais, I. A., Arisio, R., ... Yu, H. (2004). Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecologic Oncology, 94(3), 685-692. https://doi.org/10.1016/j.ygyno.2004.06.018

Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. / Katsaros, D.; Cho, W.; Singal, R.; Fracchioli, S.; Rigault De La Longrais, I. A.; Arisio, R.; Massobrio, M.; Smith, M.; Zheng, Wenxin -; Glass, J.; Yu, H.

In: Gynecologic Oncology, Vol. 94, No. 3, 09.2004, p. 685-692.

Research output: Contribution to journalArticle

Katsaros, D, Cho, W, Singal, R, Fracchioli, S, Rigault De La Longrais, IA, Arisio, R, Massobrio, M, Smith, M, Zheng, W, Glass, J & Yu, H 2004, 'Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer', Gynecologic Oncology, vol. 94, no. 3, pp. 685-692. https://doi.org/10.1016/j.ygyno.2004.06.018
Katsaros D, Cho W, Singal R, Fracchioli S, Rigault De La Longrais IA, Arisio R et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecologic Oncology. 2004 Sep;94(3):685-692. https://doi.org/10.1016/j.ygyno.2004.06.018
Katsaros, D. ; Cho, W. ; Singal, R. ; Fracchioli, S. ; Rigault De La Longrais, I. A. ; Arisio, R. ; Massobrio, M. ; Smith, M. ; Zheng, Wenxin - ; Glass, J. ; Yu, H. / Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. In: Gynecologic Oncology. 2004 ; Vol. 94, No. 3. pp. 685-692.
@article{c06636e1200d4aa4bb551fe4a0ed7972,
title = "Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer",
abstract = "Objective. Methylation of p16 promoter was evaluated in ovarian cancer to determine the role of p16 methylation in ovarian cancer prognosis. Methods. Two hundred and forty-nine patients with primary epithelial ovarian cancer were selected for the study; these patients were followed for a median of 31 months. Genomic DNA extracted from fresh frozen tumor tissues were treated with sodium bisulfite and were analyzed for p16 methylation using methylation-specific PCR (MSP). Cox regression survival analysis was performed to examine the associations of p16 methylation with progression-free and overall survivals. Results. Of the 249 patients, 100 (40{\%}) were tested positive for p16 promoter methylation. The status of p16 methylation did not change significantly with patient age, disease stage, histological grade, residual tumor size, and debulking results, although p16 methylation seemed to occur more often in patients with advanced diseases or aggressive tumors. Compared to those without p16 methylation, patients with p16 methylation had significantly higher risk for disease progression (P = 0.01). The relative risk for progression was 1.69 (95{\%} CI: 1.12-2.54), and the association remained statistically significant (RR = 1.54, 95{\%} CI: 1.01-2.34) after adjusting for clinical and pathological variables. The risk for death was also higher in methylation positive patients than in methylation negative patients (RR = 1.33, 95{\%} CI: 0.88-2.00), but the difference was not statistically significant. Conclusion. The study suggests that promoter methylation in the p16 gene is associated with ovarian cancer progression, and evaluation of p16 methylation may have values in predicting ovarian cancer prognosis.",
keywords = "Epithelial ovarian cancer, Methylation, p16",
author = "D. Katsaros and W. Cho and R. Singal and S. Fracchioli and {Rigault De La Longrais}, {I. A.} and R. Arisio and M. Massobrio and M. Smith and Zheng, {Wenxin -} and J. Glass and H. Yu",
year = "2004",
month = "9",
doi = "10.1016/j.ygyno.2004.06.018",
language = "English (US)",
volume = "94",
pages = "685--692",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer

AU - Katsaros, D.

AU - Cho, W.

AU - Singal, R.

AU - Fracchioli, S.

AU - Rigault De La Longrais, I. A.

AU - Arisio, R.

AU - Massobrio, M.

AU - Smith, M.

AU - Zheng, Wenxin -

AU - Glass, J.

AU - Yu, H.

PY - 2004/9

Y1 - 2004/9

N2 - Objective. Methylation of p16 promoter was evaluated in ovarian cancer to determine the role of p16 methylation in ovarian cancer prognosis. Methods. Two hundred and forty-nine patients with primary epithelial ovarian cancer were selected for the study; these patients were followed for a median of 31 months. Genomic DNA extracted from fresh frozen tumor tissues were treated with sodium bisulfite and were analyzed for p16 methylation using methylation-specific PCR (MSP). Cox regression survival analysis was performed to examine the associations of p16 methylation with progression-free and overall survivals. Results. Of the 249 patients, 100 (40%) were tested positive for p16 promoter methylation. The status of p16 methylation did not change significantly with patient age, disease stage, histological grade, residual tumor size, and debulking results, although p16 methylation seemed to occur more often in patients with advanced diseases or aggressive tumors. Compared to those without p16 methylation, patients with p16 methylation had significantly higher risk for disease progression (P = 0.01). The relative risk for progression was 1.69 (95% CI: 1.12-2.54), and the association remained statistically significant (RR = 1.54, 95% CI: 1.01-2.34) after adjusting for clinical and pathological variables. The risk for death was also higher in methylation positive patients than in methylation negative patients (RR = 1.33, 95% CI: 0.88-2.00), but the difference was not statistically significant. Conclusion. The study suggests that promoter methylation in the p16 gene is associated with ovarian cancer progression, and evaluation of p16 methylation may have values in predicting ovarian cancer prognosis.

AB - Objective. Methylation of p16 promoter was evaluated in ovarian cancer to determine the role of p16 methylation in ovarian cancer prognosis. Methods. Two hundred and forty-nine patients with primary epithelial ovarian cancer were selected for the study; these patients were followed for a median of 31 months. Genomic DNA extracted from fresh frozen tumor tissues were treated with sodium bisulfite and were analyzed for p16 methylation using methylation-specific PCR (MSP). Cox regression survival analysis was performed to examine the associations of p16 methylation with progression-free and overall survivals. Results. Of the 249 patients, 100 (40%) were tested positive for p16 promoter methylation. The status of p16 methylation did not change significantly with patient age, disease stage, histological grade, residual tumor size, and debulking results, although p16 methylation seemed to occur more often in patients with advanced diseases or aggressive tumors. Compared to those without p16 methylation, patients with p16 methylation had significantly higher risk for disease progression (P = 0.01). The relative risk for progression was 1.69 (95% CI: 1.12-2.54), and the association remained statistically significant (RR = 1.54, 95% CI: 1.01-2.34) after adjusting for clinical and pathological variables. The risk for death was also higher in methylation positive patients than in methylation negative patients (RR = 1.33, 95% CI: 0.88-2.00), but the difference was not statistically significant. Conclusion. The study suggests that promoter methylation in the p16 gene is associated with ovarian cancer progression, and evaluation of p16 methylation may have values in predicting ovarian cancer prognosis.

KW - Epithelial ovarian cancer

KW - Methylation

KW - p16

UR - http://www.scopus.com/inward/record.url?scp=4444284167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444284167&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.06.018

DO - 10.1016/j.ygyno.2004.06.018

M3 - Article

VL - 94

SP - 685

EP - 692

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -